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Abstract 
Background: Cephalosporins are one of the most 
widely and generously used antibiotics in treatment 
of infections in patients admitted to the hospital. 
However due to their over use, resistance to 3rd 
generation cephalosporins like ceftriaxone is 
becoming increasingly widespread. The aim of the 
study was the assessment of prevalence of microbial 
resistance to above mentioned drug in the pediatric 
intensive care units of Holy Family Hospital and 
Benazir Bhutto Hospital when used in treatment for 
bacterial infections. 
Methods: In this descriptive cross-sectional study, 
253 pediatric patients of pediatric intensive care 
units, data was taken from records of the Pathology 
Department of Holy Family Hospital and Benzair 
Bhutto Hospital from the September 2016 to July 
2017. Collected data includes the information 
regarding the culture positive microbes, and the 
antibiotic sensitivity of the bacterial isolates. The 
Bauer-Kirby Disk Diffusion method was 
meticulously used to detect the antimicrobial 
susceptibility.  
Results: In the period from September 2016 to July 
2017, specimens taken from 253 patients admitted to 
Pediatric intensive care units were sent for culture 
and sensitivity to pathology lab. Out of these 
specimens 61.9% showed no growth while 35.1% 
showed bacterial growth and 3 % showed fungal 
growth. Of the specimen that showed bacterial 
growth, Ceftriaxone was tested against Klebsiella, 
Acinetobacter, Pseudomonas, E.Coli, Staphylococcus 
Aureus and Salmonella. In this study the overall 
resistance for Ceftriaxone was 92.3%. In the data 
collected, Ceftriaxone showed 93.1% resistance in 
Holy Family Hospital and 96.4% in Benazir Bhutto 
Hospital. 
Conclusion: In light of previous relevant studies, 
our study shows further decline in effectiveness 
Ceftriaxone when used in treatment against bacterial 
infection in pediatric intensive care units. 
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Introduction 
A major conundrum for the intensive 
management worldwide is the emergence of 
antibiotic resistance. The excessive use of 
antibiotics has been attributed to increasing drug 
resistance in the ICU and remains the vital 
contributing factor to the development of 
antibiotic resistance. An overall marked 
difference was reported when a comparison was 
made between the prevalence of antibiotic 
resistance in the general versus the intensive care 
setting.1 In 2016, United Nations held a meeting 
on antimicrobial resistance, low and middle 
income countries were predicted to have the 
greatest problems in managing drug resistance 
and the subsequent burden of disease. Also, due 
to limited access to diagnostic modalities, 
treatment of bacterial infections in individual 
patients is largely empirical.2 Bacteria have a 
remarkable number of genetic mechanisms for 
developing antimicrobial resistance.3In order to 
optimize antibiotic therapy, antibiotic 
surveillance is essential.4Monitoring and 
controlling antimicrobial resistance is 
particularly troublesome in developing countries 
as lack of surveillance systems, limited resources, 
poor adherence to infection control measures, 
injudicious use of antibiotics, and limited 
antimicrobial formulary all accentuate the 
problem.5 The emergence of antimicrobial-
resistant pathogens in ICUs has made treating 
infections very difficult and, in some cases, 
impossible.6 A recent cross sectional, 
observational study done in Holy Family 
Hospital, Pakistan in order to highlight the 
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overall patterns of predominance for bacterial 
infections and their sensitivities reported by 
culturing the isolated organisms in patients 
admitted to a medical intensive care unit (ICU) 
through January to October, 2011 showed E. Coli 
as the main pathogen causing infection in the 
ICU setting, and majority of its strains showed 
resistant to both Ceftriaxone.  
Antibiotics are the most commonly used 
medicines in the Intensive Care Units (ICUs).7 
Empiric management requires strict scrutiny and 
vigilance in critically ill patients, which is 
broadly dependent on the carefully chosen 
antibiotic regimes.8 Appropriate therapy of ICU 
infections directed by local resistance data can 
have significant consequences for both patient 
and the healthcare system.9 Unchecked use of 
Ceftriaxone is leading to microbes becoming 
increasingly resistant. Antibiotic-resistant 
pathogens have more bearing on the duration of 
illness as compared to the actual length of 
treatment.10 This research was carried out in the 
intensive wings of the Pediatric departments of 
Benazir Bhutto Hospital and Holy Family 
Hospital, Rawalpindi to assess the resistance 
against the above mentioned drug when used to 
treat serious infections in the pediatric age group. 
This study will help to judge the current 
effectiveness of Ceftriaxone when used in the 
treatment of infections in the pediatric ICU 
setting. 
 
Materials and Methods: 
This descriptive cross-sectional study was initiated 
after taking formal permission from the concerned 
authorities and study was carried out in Pathology 
Department of Holy Family Hospital (HFH) and 
Benazir Bhutto hospital (BBH), for the duration of 3 
months from June 2017 to August 2017. From records 
(September 2016 to July 2017) of Pathology 
Department, data of PICU patients having any 
infection was included. Cultures were taken from CSF, 
Blood, Urine, Respiratory Secretions, Peritoneal Fluid 
and others. 
Anticipated population proportion is 0.207. Keeping 
level of confidence 95% and absolute precision 0.05%, 
minimally required sample size calculated through 
WHO sample size calculator was 253. 
All the 253 patients from the records were included 
using simple random sampling technique. A 
structured pro-forma was designed where information 
regarding the type of specimen evaluated, culture 
results, and the sensitivity patterns of the bacterial 
isolates concerning ceftriaxone, extracted from records 
were noted. The Bauer-Kirby Disk Diffusion method 
was meticulously used to detect the antimicrobial 
susceptibility. Temperature used for incubation was 
37℃ and overnight aerobic incubation (18-24hours) 
was carried out. 1 petri dish for culture and 1 for 
sensitivity was used. Strength of Ceftriaxone used was 
30mcg. CLSI guidelines were followed for all the 
procedures mentioned. Statistical Package of Social 
Sciences (Version-22) for windows was used for the 
entry and analysis where descriptive statistics like 
percentages, frequencies, means, and standard 
deviations along with cross tabulations were 
formulated. 
Results 
In the period from September 2016 to July 2017, 
specimens taken from 253 patients admitted to 
Pediatric intensive care units were sent for culture and 
sensitivity to pathology laboratory. Out of these 
specimens 61.9% showed no growth while 35.1% 
showed bacterial growth and 3 % showed fungal 
growth. . Of the specimen that showed bacterial 
growth, Ceftriaxone was tested against Klebsiella, 
Acinetobacter, Pseudomonas, E.Coli, Staphylococcus 
Aureus and Salmonella. In this study the overall 
resistance for Ceftriaxone was 92.3% (Table I). 
Table I: Percentage resistance of microbiological 
isolates against ceftriaxone 
 
In the data from Holy Family Hospital , Ceftriaxone 
showed 93.1% resistance and 96.4% in Benazir Bhutto 
Hospital illustrated in Fig I. 
 
Figure I: The sensitivity and resistance patterns of 
ceftriaxone in Holy Family Hospital and Benazir 
Bhutto Hospital. 
 Frequency Percent Valid Percent 
Sensitive 5 1.9 7.7 
Resistance 60 22.6 92.3 
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Our study showed that the most common pathogen 
isolated, E.Coli was 95.7% to Ceftriaxone. When tested 
for strains of Klebsiella, resistance was 100% for 
Ceftriaxone. Acinetobacter had 93.8% resistance to 
Ceftriaxone. Other significant findings in our study 
included Pseudomonas Aeruginosa having 85.7% 
resistance to Ceftriaxone explained in fig II. 
 
Figure II: Patterns of sensitivity and resistance of the 
individual isolates 
 
Pathogen Sensitive 
(Count) 
Resistant 
(Count) 
Klebsiella 0 16 
Acinetobacter 1 15 
Pseudomonas 1 6 
E. Coli 1 22 
Staphylococcus Aureas 1 0 
Salmonella 1 1 
Table II: Sensitivity Pattern of different Microbial 
Isolates to Ceftriaxone 
 
 
Discussion 
Empiric management is the main initial stance of 
the intensive care setting. Among the admitted 
infants and children around 35% receive 
antibiotics.11 Resistance to antimicrobial drugs is 
increasing rapidly worldwide in almost all 
bacterial genera and to almost all drug classes.12 
Multi resistant pathogens causing infections are a 
threat to critically ill patients all around the 
world.13 Hence, a continuous scrutiny of the 
patterns of antibiotic sensitivity among the 
common bacterial isolates is necessary to register 
any change in these patterns to effectively 
manage patients in intensive settings. This, a 
more targeted, not only provides an effective 
management plan for the patient but also 
prevents the emergence of microbial resistance to 
antibiotics.1 Multiple researches across the globe 
have shown that antibiotic resistance is a major 
issue and yet there is a lack of comprehensive 
data regarding this issue in our health system 
especially in pediatric Intensive Care Units.  
 
The predominant organism causing infection in 
pediatric intensive care units was E.Coli, which 
was similar to a study carried out in the Medical 
intensive care unit of Holy Family Hospital, 
Pakistan. That study’s result showed 80.0% of 
E.Coli strains being resistant to Ceftriaxone while 
in our data, this percentage rose to 95.7%.9 To put 
the gravity of situation into perspective, a study 
conducted in Rwanda showed 55.0% of 
Klebsiella strains resistant to Ceftriaxone. In our 
study, however, 100% of Klebsiella strains 
showed resistance to Ceftriaxone.5 The same 
study showed Acinetobacter having resistance of 
40% to Ceftriaxone, while these values were 
found to be at 93.8% showing drastically 
increasing trends of microbial resistance.5 A 
study conducted in Indonesia showed a different 
trend, with pseudomonas species being the most 
common organisms causing infection in the ICU 
setting. Their study showed 60.9% strains of 
Pseudomonas Aeuroginosa resistant to 
Ceftriaxone whereas this percentage was 85.7% 
in our study.1 A study performed in Nepal in 
2005 showed Pseudomonas strains as having 
50% sensitivity to ceftriaxone in the ICU setting. 
This percentage has now plummeted and in our 
study 85.7% of infections caused by 
Pseudomonas strains were resistant to 
ceftriaxone, frequency tabulated in table 2.14 A 
study conducted in Canada also revealed Multi 
Drug Resistant strains of Pseudomonas 
Aeruginosa in ICU.15 
 
Conclusion 
Our study has shown, increasing trends of anti-
microbial resistance to Ceftriaxone compared to 
previous studies. Prominent findings included 100% 
resistance of Klebsiella strains to Ceftriaxone and 
increase in resistance of E.Coli, Acinetobacter, 
Pseudomonas and Staphylococcus Aureus to 
Ceftriaxone. 
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